Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Eyes Booster Dose Trial Launch in January
Daiichi Sankyo is in discussions with Japanese regulatory authorities on its plan to begin a booster dose trial for its investigational COVID-19 vaccine DS-5670 in January next year, the company said on October 21 as it announced positive data from…
To read the full story
Related Article
- Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
- Daiichi Sankyo’s COVID Jab Hits Mark in Japan Booster Trial, Filing Set for January
November 16, 2022
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- COVID-19 Booster Study Shows Efficacy: Daiichi Sankyo
May 27, 2022
- Daiichi Sankyo Begins PII for COVID-19 mRNA Vaccine, Eyes 2022 Rollout
November 18, 2021
BUSINESS
- Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
- Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…